NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong reminds investors of an investigation concerning whether Endo International plc (“Endo”) (NASDAQ: ENDP) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/ENDP-Info-Request-Form-1642. There is no cost or obligation to you.
On June 8, 2017, the U.S. Food and Drug Administration (the “FDA”) requested Endo pull its opioid painkiller OPANA ER off the U.S. market. According to the FDA, Opana’s “high risk of abuse and potential to help spread HIV and hepatitis C” necessitated its removal from the market.
To learn more about the investigation of Endo contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://docs.wongesq.com/ENDP-Info-Request-Form-1642.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.